Hemab Therapeutics names Keli Walbert to board, adds her to audit committee

• Hemab Therapeutics appointed Keli Walbert to its board, effective Sept. 24, 2026.
• Walbert will join the board’s Audit Committee, replacing Akshay Vaishnaw.
• Walbert most recently served as executive vice president of U.S. commercial at Horizon Therapeutics.
• Her background includes commercial leadership roles at AbbVie, the American Medical Association, Abbott, United Healthcare.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241601PRIMZONEFULLFEED9833547) on September 24, 2026, and is solely responsible for the information contained therein.